{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:09:54Z","timestamp":1731388194072,"version":"3.28.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,11]]},"DOI":"10.7759\/cureus.73435","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:12:45Z","timestamp":1731334365000},"source":"Crossref","is-referenced-by-count":0,"title":["Parathyroid Hormone-Mediated Hypercalcemia With Remarkable Bone Mineral Density Recovery After Multiple Zoledronic Acid Infusions"],"prefix":"10.7759","author":[{"given":"Meumbur P","family":"Kpughur-Tule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly M","family":"Hubers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahvish","family":"Renzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M","family":"Satei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hypercalcemia","author":"Sadiq NM","year":"2024","unstructured":"Sadiq NM, Anastasopoulou C, Patel G, Badireddy M. Hypercalcemia. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081604","article-title":"Primary hyperparathyroidism: a narrative review of diagnosis and medical management","volume":"10","author":"Dandurand K","year":"2021","unstructured":"Dandurand K, Ali DS, Khan AA. Primary hyperparathyroidism: a narrative review of diagnosis and medical management. J Clin Med. 2021, 10:1604. 10.3390\/jcm10081604","journal-title":"J Clin Med"},{"key":"ref3","article-title":"Malignancy-Related Hypercalcemia","author":"Vakiti A","year":"2024","unstructured":"Vakiti A, Anastasopoulou C, Mewawalla P. Malignancy-Related Hypercalcemia. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref4","article-title":"Zoledronate","author":"Greear EL","year":"2024","unstructured":"Greear EL, Patel P, Bankole A. Zoledronate. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black DM","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al.. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356:1809-22. 10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000585","article-title":"Bisphosphonate therapy in CKD: the current state of affairs","volume":"29","author":"Damasiewicz MJ","year":"2020","unstructured":"Damasiewicz MJ, Nickolas TL. Bisphosphonate therapy in CKD: the current state of affairs. Curr Opin Nephrol Hypertens. 2020, 29:221-6. 10.1097\/MNH.0000000000000585","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint ND","year":"2009","unstructured":"Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol. 2009, 4:221-33. 10.2215\/CJN.02550508","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S349604","article-title":"The mechanism of bone remodeling after bone aging","volume":"17","author":"Fang H","year":"2022","unstructured":"Fang H, Deng Z, Liu J, Chen S, Deng Z, Li W. The mechanism of bone remodeling after bone aging. Clin Interv Aging. 2022, 17:405-15. 10.2147\/CIA.S349604","journal-title":"Clin Interv Aging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03695-y","article-title":"Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature","volume":"16","author":"Nurmi-L\u00fcthje I","year":"2022","unstructured":"Nurmi-L\u00fcthje I, L\u00fcthje P. Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature. J Med Case Rep. 2022, 16:473. 10.1186\/s13256-022-03695-y","journal-title":"J Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312592-parathyroid-hormone-mediated-hypercalcemia-with-remarkable-bone-mineral-density-recovery-after-multiple-zoledronic-acid-infusions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T14:12:47Z","timestamp":1731334367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312592-parathyroid-hormone-mediated-hypercalcemia-with-remarkable-bone-mineral-density-recovery-after-multiple-zoledronic-acid-infusions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.73435","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}